Company Growth (employees)
AstraZeneca was founded in 1999 and is headquartered in Cambridge, GB
Key People at AstraZeneca
Pascal Soriot
Executive Director and Chief Executive Officer
Marc Dunoyer
CFO
Herren Wu
CTO
Bahija Jallal
Executive Vice President
Menelas Pangalos
Executive Vice President
Mark Mallon
Executive Vice President
Jeff Pott
General Counsel
Katarina Ageborg
Chief Compliance Officer
Caroline Hempstead
Executive Vice President, Human Resources and Corporate Affairs (interim)
Pam Cheng
Executive Vice-President
Fiona Cicconi
Executive Vice-President, Human Resources
AstraZeneca Office Locations
AstraZeneca has offices in Cambridge, London, Bangalore, Hong Kong and in 169 other locations
Wedel, DE
Wedel, Tinsdaler Weg 183
Wilmington, US
1800 Concord Pike, P.O. Box 15437
Osaka, JP
Grand Front Osaka Tower B, 3 1, Ofuka Cho, Kita Ku
Shanghai, CN
43/F Citic Square, 1168 Nan Jing Xi Road
Hong Kong, HK
18/F, Shui On Centre, 6 8 Harbour Road, Wanchai
Bangalore, IN
Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road
London, GB
15 Stanhope Gate
AstraZeneca Data and Metrics
AstraZeneca Financial Metrics
AstraZeneca's revenue was reported to be $23.6 b in FY, 2015 which is a 9% decrease from the previous period.
Numbers are in $, USD
Revenue (FY, 2015) | 23.6 b |
Revenue growth (FY, 2014 - FY, 2015), % | (9%) |
Gross profit (FY, 2015) | 19 b |
Gross profit margin (FY, 2015), % | 80% |
Net income (FY, 2015) | 2.8 b |
Market capitalization (26-May-2017) | 85.7 b |
Closing share price (26-May-2017) | 34.3 |
Cash (31-Dec-2015) | 4.6 b |
AstraZeneca's current market capitalization is $85.7 b.
- Source: Company Filings
| Numbers are in $, USD | FY, 2013 | FY, 2014 | FY, 2015 |
|---|---|---|---|
Revenue | 25.7 b | 26.1 b | 23.6 b |
Revenue growth, % | 1% | (9%) | |
Cost of goods sold | 5.3 b | 5.8 b | 4.6 b |
Gross profit | 20.5 b | 20.3 b | 19 b |
Gross profit Margin, % | 80% | 78% | 80% |
Sales and marketing expense | 306 m | 324 m | 339 m |
R&D expense | 4.8 b | 5.6 b | 6 b |
General and administrative expense | 12.2 b | 13 b | 11.1 b |
Operating expense total | 17.3 b | 18.9 b | 17.4 b |
Depreciation and amortization | 4.6 b | 3.3 b | 2.9 b |
Interest expense | (495 m) | (963 m) | (1.1 b) |
Interest income | 50 m | 78 m | 46 m |
Pre tax profit | 2.1 b | 921.4 m | 2.3 b |
Income tax expense | (696 m) | (11 m) | (243 m) |
Net Income | 2.6 b | 1.2 b | 2.8 b |
- Source: Company Filings
| Numbers are in £, GBP | FY, 2013 | FY, 2014 | FY, 2015 |
|---|---|---|---|
Cash | 6.1 b | 4.7 b | 4.6 b |
Accounts Receivable | 3.6 b | 3.5 b | 3.4 b |
Current Assets | 13.2 b | 12.2 b | 11.7 b |
PP&E | 6.4 b | 7 b | 7.2 b |
Goodwill | 17.1 b | 24.1 b | 25.5 b |
Total Assets | 36.8 b | 43.3 b | 44.5 b |
Accounts Payable | 1.6 b | 2.6 b | 2.6 b |
Current Liabilities | 10.6 b | 12.8 b | 11 b |
Retained Earnings | 1.7 b | (1.7 b) | (488.1 m) |
Total Equity | 15.3 b | 14.5 b | 13.7 b |
Financial Leverage | 2.4 x | 3 x | 3.3 x |
| Numbers are in $, USD | FY, 2013 | FY, 2014 | FY, 2015 |
|---|---|---|---|
Cash From Operating Activities | 7.4 b | 7.1 b | 3.3 b |
Cash From Financing Activities | (2 b) | (2 b) | 649.3 m |
Income Taxes Paid | (457.7 m) | (8.1 m) | (179.7 m) |
| Numbers are in $, USD | Y, 2015 |
|---|---|
Revenue/Employee | 453.7 k |
Financial Leverage | 3.3 x |
AstraZeneca Operating Metrics
| Y, 2013 | Y, 2014 | Y, 2015 | Y, 2016 | |
|---|---|---|---|---|
Projects in R&D Pipeline | 99B | 133C | 146A | 132D |
Phase III Trials | 19 | 11 | 35 | 27 |
NME in Late-stage Development | 7 | 13 | 15 | 12 |
Drugs Approved by FDA | 1E |
AstraZeneca Market Value History
AstraZeneca Revenue Breakdown
AstraZeneca Median Salaries
Source: 105 public H-1B filings from AstraZeneca
